Daniel Guldager Kring Rasmussen

15PUBLICATIONS
32CO-AUTHORS
Molecular targetsNanotoxicology, health and safetyPredictive and prognostic markersEnergy generation, conversion and storage (excl. chemical and electrical)Regenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Nov 25, 2023
Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes.

Alexandra Louise Møller, Stefanie Thöni, Felix Keller

|May 27, 2023
Endotrophin Levels Are Associated with Allograft Outcomes in Kidney Transplant Recipients.

Nadja Sparding, Federica Genovese, Daniel Guldager Kring Rasmussen

|Dec 19, 2022
Plasma endotrophin, reflecting tissue fibrosis, is associated with graft failure and mortality in KTRs: results from two prospective cohort studies.

Daan Kremer, Firas F Alkaff, Adrian Post

|Sep 12, 2022
Endotrophin as a Marker of Complications in a Type 2 Diabetes Cohort.

Ninna Hahn Tougaard, Alexandra Louise Møller, Pernille Falberg Rønn

|Apr 29, 2021
Endotrophin, a collagen type VI-derived matrikine, reflects the degree of renal fibrosis in patients with IgA nephropathy and in patients with ANCA-associated vasculitis.

Nadja Sparding, Federica Genovese, Daniel Guldager Kring Rasmussen

|Feb 24, 2021
Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients.

Federica Genovese, Daniel Guldager Kring Rasmussen, Morten A Karsdal

Pageof 3

Frequent Collaborators

3 joint publications

Signe Holm Nielsen

2 joint publications

Federica Genovese

2 joint publications

Mads Hornum

2 joint publications

Nadja Sparding